Publications - 'P'

Publications 651 - 675 de 2458
| % | ( | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | < | ? | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | [ | ` | {
Titre DOI
Phase 3 randomized study of daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.
P. Moreau; M. Attal; C. Hulin; M.C. Bene; A. Broijl; D. Caillot; M. Delforge; T. Dejoie; T. Facon; J. Lambert; X. Leleu; M. Macro; A. Perrot; S. Zweegman; T. Ahmadi; C. Chiu; L. Pei; J. Vermeulen; H. Avet-Loiseau; P. Sonneveld
2019
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naive, HCV GT1b-infected patients, with non-severe fibrosis
A. Abergel; T. Asselah; A. Mallat; B. Chanteranne; F. Faure; D. Larrey; J. Gournay; V. Loustaud-Ratti; V. Di Martino; I. Fouchard-Hubert; S. Pol; F. Bailly; D. Samuel; A. Tran; M. Dodel; N. Andant; G. Lamblin; L. Muti; M. Reymond; C. Teilhet; B. Pereira; B. Buchard
2020 		10.1111/liv.14502, Early Access Date = {JUN 2020
Phase control of two-color filamentation
J. Doussot; P. Bejot; G. Karras; F. Billard; O. Faucher
2015 		10.1088/0953-4075/48/18/184005
Phase evolution of Peregrine-like breathers in optics and hydrodynamics
G. Xu; K. Hammani; A. Chabchoub; J.M. Dudley; B. Kibler; C. Finot
2019 		10.1103/PhysRevE.99.012207
Phase I dose-finding and pharmacokinetic study of IV vinflunine in combination with methotrexate in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) previously treated with platinum-based chemotherapy.
A. Mailliez; F. Rolland; J.Marc Tourani; C. Lafond; D. Cupissol; N. Isambert
2015 		10.1200/jco.2015.33.15_suppl.e17049
Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients
J. Medioni; G. Deplanque; J.M. Ferrero; T. Maurina; J.M.P. Rodier; E. Raymond; J. Allyon; G. Maruani; P. Houillier; S. Mackenzie; S. Renaux; J.F. Dufour-Lamartinie; R. Elaidi; C. Lerest; S. Oudard
2014 		10.1158/1078-0432.CCR-13-3247
Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors
D.D. Von Hoff; D.W. Rasco; E.I. Heath; P.N. Munster; J.H.M. Schellens; N. Isambert; C. Le Tourneau; B. O'Neill; R.H.J. Mathijssen; J.A. Lopez-Martin; J. Edenfiele; M. Martin; P.M. LoRusso; G.L. Bray; J. DiMartino; A. Nguyen; K. Liu; E. Laille; J.C. Bendell
2018 		10.1158/1078-0432.CCR-17-3716
Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
A. Hollebecque; J.S. de Bono; R. Plummer; N. Isambert; P. Martin-Romano; E. Baudin; S. Mora; E. Filvaroff; M. Lamba; Z. Nikolova
2019
Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
A. Hollebecque; J. de Bono; R. Plummer; N. Isambert; P. Martin-Romano; E. Baudin; S. Mora; A. Harding; A. Nguyen; E. Filvaroff; M. Lamba; K. Liu; J. De Alvaro; J. DiMartino; M. Zuraek; Z. Nikolova
2018
Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
A. Hollebecque; J. de Bono; R. Plummer; N. Isambert; P. Martin-Romano; E. Baudin; S. Mora; A. Harding; A. Nguyen; E. Filvaroff; M. Lamba; K. Liu; J. De Alvaro; J. DiMartino; M. Zuraek; Z. Nikolova
2018
Phase I study of CC-90011 in patients with advanced solid tumours (STs) and relapsed/refractory non-hodgkin lymphoma (R/R NHL)
A. Hollebecque; J.S. de Bono; S. Salvagni; R. Plummer; N. Isambert; P. Niccoli; J. Capdevila; G. Curigliano; V. Moreno; F.G.M. De Braud; M. Lopez-Brea; P. Martin-Romano; E. Baudin; M. Arias; J. De Alvaro; J. Parra-Palau; S. Perez; E. Filvaroff; M. Lamba; Z. Nikolova
2019
Phase I study of pan-histone deacetylase inhibitor abexinostat in combination with cisplatin in patients with advanced solid tumors
M. Campone; N. Isambert; R. Sabatier; H. Castanie; S. Zanetta; I. Sudey; F. Cantero; J. Pauly; E. Leroux; S. Malasse; A. Goncalves
2014 		10.1016/S0959-8049(14)70712-9
Phase I trial evaluating panitumumab in combination with chemoradiotherapy for anal cancers
V. Vendrely; C. Lemanski; E. Le Prise; E. Maillard; X. Mirabel; G. Lledo; L. Dahan; A. Adenis; G. Paintaud; T. Lecomte; C. Levy-Piedbois; E. Terrebonne; V. Mammar; S. Manfredi; T. Aparicio
2017 		10.1016/S0167-8140(17)31139-8
Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody (R), in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours
N. Girard; M. Wermke; F. Barlesi; D.W. Kim; F. Ghiringhelli; H.T. Landsteiner; G. Jayadeva; J. Alt; B. Hackanson
2020 		10.1016/j.annonc.2020.08.647
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer
J.D. Fumet; N. Isambert; A. Hervieu; S. Zanetta; J.F. Guion; A. Hennequin; E. Rederstorff; A. Bertaut; F. Ghiringhelli
2018 		10.1136/esmoopen-2018-000375
Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer
M. Jary; F. Ghiringhelli; M. Jacquin; F. Fein; T. Nguyen; D. Cleau; V. Nerich; M.El Gani; P. Mathieu; S. Valmary-Degano; L. Arnould; C. Lassabe; N. Lamfichekh; S. Fratte; S. Paget-Bailly; F. Bonnetain; C. Borg; S. Kim
2014 		10.1007/s00280-014-2482-0
Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification.
C. Lebbe; S. Chevret; T. Jouary; S. Dalac; S. Dalle; B. Guillot; J.P. Arnault; M.F. Avril; C. Bedane; G. Bens; M. -Beylot-Barry; S. Mansard; F. Grange; N. Meyer; L. Machet; L. Misery; P. Saiag; M. Battistella; S. Mourah; N. Dumaz; G.C.C.Grp Franca Cuta
2014 		10.1200/jco.2014.32.15_suppl.9032
Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification: Results of the pharmacodynamic study.
E. Lesteven; M. Battistella; T. Jouary; S. Dalac; S. Dalle; B. Guillot; J.P. Arnault; M.F. Avril; C. Bedane; G. Bens; M. Beylot-Barry; F. Grange; N. Meyer; L. Machet; P. Saiag; N. Dumaz; S. Mourah; C. Lebbe
2015
Phase II study evaluating trifluridine/tipiracil plus bevacizumab and capecitabine plus bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysi
K. Lesniewski-Kmak; V. Moiseenko; M. Saunders; H. Wasan; G. Argiles; C. Borg; G. Creemers; M. Fedyanin; R. Glynne-Jones; P. Pfeiffer; C. Punt; D. Stroyakovskiy; T. Tije; A. van de Wouw; A. Kanehisa; R. Fougeray; L. Busto; N. Amellal; E. Van Cutsem
2018 		10.1093/annonc/mdy149.021
Phase II study evaluating trifluridine/tipiracil plus bevacizumab and capecitabine plus bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis o
E. Van Cutsem; I. Danielewicz; M.P. Saunders; P. Pfeiffer; G. Argiles; C. Borg; R. Glynne-Jones; C.J.A. Punt; A.J. van de Wouw; M. Fedyanin; D. Stroyakovskiy; H. Kroening; P. Garcia-Alfonso; H.Singh Wasan; A. Falcone; P. Aubel; A. Egorov; N. Amellal; V. Moiseenko
2021 		10.1200/JCO.2021.39.3_suppl.14
Phase II Study of a Platinum-Based Adapted Chemotherapy Regimen Combined with Radiotherapy in Patients 75 Years and Older with Esophageal Cancer
S. Servagi-Vernat; G. Crehange; B. Roullet; V. Guimas; P. Maingon; M. Puyraveau; J.Francois Bosset
2015 		10.1007/s40266-015-0275-8
Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by F-18-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study)
P. Vera; S. Thureau; P. Chaumet-Riffaud; R. Modzelewski; P. Bohn; M. Vermandel; S. Hapdey; A. Pallardy; M.A. Mahe; M. Lacombe; P. Boisselier; S. Guillemard; P. Olivier; V. Beckendorf; N. Salem; N. Charrier; E. Chajon; A. Devillers; N. Aide; S. Danhier; F. Denis; J.P. Muratet; E. Martin; A.Berriolo Riedinger; H. Kolesnikov-Gauthier; E. Dansin; C. Massabeau; F. Courbon; M.P.Farcy Jacquet; P.O. Kotzki; C. Houzard; F. Mornex; L. Vervueren; A. Paumier; P. Fernandez; M. Salaun; B. Dubray
2017 		10.2967/jnumed.116.188367
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial
P. Rodon; C. Hulin; B. Pegourie; M. Tiab; B. Anglaret; L. Benboubker; H. Jardel; O. Decaux; B. Kolb; M. Roussel; L. Garderet; X. Leleu; O. Fitoussi; C. Chaleteix; P. Casassus; P. Lenain; B. Royer; A. Banos; R. Benramdane; P. Cony-Makhoul; M. Dib; J. Fontan; A.M. Stoppa; C. Traulle; J.P. Vilque; M.O. Petillon; C. Mathiot; T. Dejoie; H. Avet-Loiseau; P. Moreau
2015 		10.3324/haematol.2014.110890
Phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial.
J. Tredaniel; F. Barlesi; C. Le Pechoux; D. Lerouge; E. Pichon; S. Le Moulec; L. Moreau; S. Friard; V. Westeel; L. Petit; O. Carre; F. Guichard; O. Raffy; J. Villa; A. Prevost; M.Paule Lebitasy; F. Morin; G. Zalcman; F. Mornex; F.Intergrp T. IFCT
2014
Phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial.
J. Tredaniel; F. Barlesi; C. Le Pechoux; D. Lerouge; E. Pichon; S. Le Moulec; L. Moreau; S. Friard; V. Westeel; L. Petit; O. Carre; F. Guichard; O. Raffy; J. Villa; A. Prevost; M.Paule Lebitasy; F. Morin; G. Zalcman; F. Mornex; F.Intergrp T. IFCT
2014

Pages